DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
Pivotal trial of Saxenda (liraglutide 3.0 mg) for chronic weight management.
SCALE Obesity and Prediabetes randomized 3,731 adults with overweight (plus comorbidity) or obesity, without diabetes, to liraglutide 3.0 mg daily or placebo over 56 weeks. Mean weight loss: 8.0% liraglutide vs 2.6% placebo; 63.2% lost ≥5% vs 27.1% placebo. Pivotal trial behind Saxenda's FDA approval (2014). First weight-loss GLP-1 to gain FDA approval. NEJM 2015.